¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-19
±³À°ÀÏÀÚ : 2020-11-19
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2020 KALC International Conference      
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ½ÉÇöÁ¤ 
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:00~08:25 Extracellular Vesicle Liquid Biopsy  ÇãÀ翵(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:25~08:50 Multiplex Molecular and Histopathology in Lung Cancer  ±èÅÂÁ¤(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:50~09:15 Liquid Biopsy Approaches for EGFR Mutant NSCLC Patients  Therese Becker(Ingham Institute for Applied Medical Research) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 09:15~09:40 High-plex Methods for Biomarker Discovery  David Rimm(Yale University School of Medicine) 
È޽Ġ11¿ù 19ÀÏ  09:40~09:50 Break  () 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 09:50~10:40 ¡°Turn Your Face To Hope For The Patients¡±: Pembrolizumab in the 1st-line metastatic squamous NSCLC  ÀÓ¼±¹Î(ºÐ´ç¼­¿ïÀÇ´ë) 
È޽Ġ11¿ù 19ÀÏ  10:40~10:50 Break  () 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:50~11:15 Incorporation of Immuno-oncology in SCLC  À̼¼ÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 11:15~11:40 Novel Therapeutic Approaches in SCLC  ÀÌ°æ¿ø(°æ»óÀÇ´ë) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 11:40~12:05 Recent Update in Thymic Malignancy Treatment  ±è¼¼Çö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 12:05~12:30 Multidisciplinary Approach for Malignant Mesothelioma  ¹ÚÁöÇö(°Ç±¹ÀÇ´ë) 
È޽Ġ11¿ù 19ÀÏ  12:30~12:40 Break  () 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 12:40~13:05 Salvage Operation after Definitive CCRTx  Jessica Donington(University of Chicago) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:05~13:30 Salvage Surgery for Advanced Non-small Cell Lung Cancer after Targeted Therapy  Tomoyuki Hishida(Keio University School of Medicine) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:30~13:55 Experience of Pulmonary Resection after Immunotherapy  ¹Ú½Â¿ë(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:55~14:20 Pulmonary Resection after Neoadjuvant Therapy  ±èÈ«°ü(¼º±Õ°üÀÇ´ë) 
È޽Ġ11¿ù 19ÀÏ  14:20~14:30 Break  () 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:30~14:55 Review of SABR versus Surgery Trials  ¿ìÈ«±Õ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:55~15:20 Surgery as a Primary Treatment for Early Lung  Masatsugu Hamaji(Kyoto University) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:20~15:45 SABR as a Primary Treatment for Early Lung Cancer  Á¶ÀçÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:45~16:10 Combination of SABR and Immunotherapy for Lung Cancer  Joe Y. Chang(The University of Texas MD Anderson Cancer Center) 
È޽Ġ11¿ù 19ÀÏ  16:10~16:20 Break  () 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:20~17:00 Clonal Heterogeneity and Lung Cancer Evolution: Lung TRACERx  Charles Swanton(Cancer Evolution and Genome Instability Laboratory) 
È޽Ġ11¿ù 19ÀÏ  17:00~17:10 Break  () 
±³À°½Ã°£ 11¿ù 19ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:10~17:50 10-Year and Beyond Results in NELSON Lung Cancer Screening Study  Harry J. de Koning(Erasmus University Medical Center) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20
´ÙÀ½±Û ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø Á¦ 146ȸ ¼ÒÈ­±â¼¾ÅÍ ¿¬¼ö±³À° : 2020-11-18
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
300 ¼­¿ï ´ëÇѳëÀκ´ÇÐȸ Á¦ 38Â÷ ÀÎÁ¤ÀÇ ¿¬¼ö°­Á : 2018-08-19 0 751 2018-08-08
299 ¼­¿ï 2018 ÀÇ·áÄ¿¹Â´ÏÄÉÀÌ¼Ç ±³À°Àü·« ¿öÅ©¼ó : 2018-08-18 0 527 2018-08-08
298 °æ±â ´ëÇÑôÃßÁ¾¾ç¿¬±¸È¸ Á¦18Â÷ Çмú´ëȸ : 2018-08-18 0 1,018 2018-08-08
297 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ iTHA (Innovation & Technology in Hip Athroplasty) : 2018-08-18 0 1,199 2018-08-08
296 ¼­¿ï ´ëÇÑÈäºÎ¿Ü°úÇÐȸ Heart Valve Disease Symposium 2018 : 2018-08-18 0 604 2018-08-08
295 ¼­¿ï °æÈñ´ëÇб³º´¿ø 2018 Kyung Hee Neurosurgery Symposium (ÀÓ¿µÁø ±³¼ö´Ô Á¤³â±â³ä ½ÉÆ÷Áö¿ò) : 2018-08-18 0 1,538 2018-08-08
294 °æ±â ´ëÇÑ°³¿øÀÇÇùÀÇȸ °­¿øÁöȸ ½ÉÆ÷Áö¿ò : 2018-08-18 0 620 2018-08-08
293 ¼­¿ï ´ëÇÑÈäºÎ¿Ü°úÇÐȸ Heart Valve Disease Symposium 2018 : 2018-08-17 0 1,086 2018-08-08
292 ¼­¿ï °æÈñ´ëÇб³º´¿ø Á¦11ȸ »êºÎÀΰú-¼Ò¾Æû¼Ò³â°ú ¼±»ý´Ôµé°ú ÇÔ²²ÇÏ´Â ¿ù·ÊÁý´ãȸ : 2018-08-17 0 915 2018-08-08
291 °­¿ø °­¿øµµÀÇ»çȸ ÀúÇ÷´çÁõ¿¡ ´ëÇÑ °íÂû : 2018-08-16 0 553 2018-08-08
290 ¼­¿ï ´ëÇѽÅÀåÇÐȸ 2018 Update on CKD-MBD: Phosphorous and Magnesium in health and disease : 2018-09-30 0 1,148 2018-07-28
289 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ ¼Ò¾ÆÁúȯ : 2018-09-29 0 856 2018-07-28
288 ¼­¿ï 2018 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Á¤½ÅÄ¡·á Àü¹®°úÁ¤ : ¿¬±Ø¼º ÀΰÝÀå¾Ö, ÀÇÁ¸¼º ÀΰÝÀå¾Ö : 2018-09-29 0 1,235 2018-07-28
287 ¼­¿ï 2018 ´ëÇÑâ»óÇÐȸ ±³À°½ÉÆ÷Áö¾ö : 2018-09-29 0 621 2018-07-28
286 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª(CSC treatment update) : 2018-09-28 0 1,103 2018-07-28
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷